Marshall Wace’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$374K Sell
6,367
-24,151
-79% -$1.01M ﹤0.01% 2628
2026
Q1
$983K Buy
+30,518
New +$1.13M ﹤0.01% 2141
2025
Q3
– Sell
-128,657
Closed -$3.48M – 3441
2025
Q2
$3.48M Buy
128,657
+120,326
+1,444% +$3.48M ﹤0.01% 1316
2025
Q1
$247K Sell
8,331
-948,246
-99% -$36.1M ﹤0.01% 2333
2024
Q4
$37.9M Buy
956,577
+846,487
+769% +$32.1M 0.05% 350
2024
Q3
$3.75M Buy
+110,090
New +$3.1M ﹤0.01% 1103
2023
Q4
– Sell
-55,031
Closed -$1.23M – 2637
2023
Q3
$1.23M Buy
55,031
+43,009
+358% +$1.11M ﹤0.01% 1427
2023
Q2
$306K Buy
+12,022
New +$291K ﹤0.01% 2134
2021
Q3
– Sell
-31,529
Closed -$1.26M – 3455
2021
Q2
$1.26M Sell
31,529
-95,011
-75% -$4.06M 0.01% 1695
2021
Q1
$6.8M Buy
+126,540
New +$7.29M 0.03% 657
2020
Q2
– Sell
-68,354
Closed -$1.66M – 1966
2020
Q1
$1.66M Buy
+68,354
New +$1.72M 0.02% 687
2019
Q3
– Sell
-235,645
Closed -$6.72M – 1946
2019
Q2
$6.72M Buy
235,645
+158,574
+206% +$3.96M 0.06% 399
2019
Q1
$1.93M Sell
77,071
-150,653
-66% -$2.88M 0.02% 746
2018
Q4
$2.87M Buy
+227,724
New +$2.69M 0.03% 637

Other funds holding VCYT

Marshall Wace's VCYT Position: Q2 2026 in Review

Marshall Wace reduced its Veracyte (VCYT) stake by 79% in Q2 2026, selling an estimated $1.01M and leaving 6,367 shares worth $374K. The position accounts for ﹤0.01% of the portfolio, ranked #2628.

Marshall Wace first reported a position in VCYT in Q4 2018 and has held it in 14 quarters since. The position peaked at $37.9M in Q4 2024. 370 funds tracked by Wall St. Rank hold VCYT as of Q2 2026.

  • Marshall Wace held 6,367 shares of Veracyte worth $374K as of Q2 2026.
  • Marshall Wace sold 24,151 Veracyte shares in Q2 2026, an estimated $1.01M.
  • Veracyte made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2628 holding.
  • Marshall Wace first reported a position in Veracyte in Q4 2018 and has held it in 14 quarters since.
  • Marshall Wace's Veracyte position peaked at $37.9M in Q4 2024.
  • 370 funds tracked by Wall St. Rank held Veracyte as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.